Volume of distribution (L/kg)       :1.4
half-life – normal/ESRD (hrs)      :1.4–11 (depends on preparation)/Unchanged
DOSE IN RENAL IMPAIRMENT
GFR (mL/MIN)
20 to 50     : Dose as in normal renal function
10 to 20     : Dose as in normal renal function. Start with small doses
<10           : Dose as in normal renal function. Start with small doses
DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES
CAPD                :Not dialysed. Dose as in GFR <10 mL/min
HD                     :Not dialysed. Dose as in GFR <10 mL/min
HDF/high flux   :Unknown dialysability. Dose as in GFR <10 mL/min
CAV/VVHD      :Unknown dialysability. Dose as in GFR 10 to 20 mL/min
IMPORTANT DRUG INTERACTIONS
Potentially hazardous interactions with other drugs
Anaesthetics: enhanced hypotensive effect
Antibacterials: metabolism accelerated by rifampicin; concentration increased by quinupristin/dalfopristin
Anti-epileptics: effect reduced by carbamazepine, barbiturates, phenytoin and primidone
Antifungals: metabolism possibly inhibited by itraconazole and ketoconazoleAntihypertensives: enhanced hypotensive effect, increased risk of first dose hypotensive effect of post-synaptic alpha-blockers; occasionally severe hypotension and heart failure with beta-blockers
Protein binding decreased in severe renal impairmentAcute renal dysfunction reported Increased incidence of side effects (headache, flushing, dizziness and peripheral oedema) in patients with ERFFor acute use, bite capsule then swallow contents with 10–50 mL water.